Summary

Persistence Market Research has recently published an extensive report on the global Preimplantation Genetic Testing (PGT) Market. This report provides a thorough analysis of the market dynamics, including key growth drivers, opportunities, restraints, and future trends. The detailed insights into the market structure are aimed at supporting stakeholders in strategic decision-making.

Key Insights:

• Preimplantation Genetic Testing Market Size (2024E): USD 0.68 Bn
• Projected Market Value (2031F): USD 1.48 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 9%

Preimplantation Genetic Testing Market - Report Scope:

The Preimplantation Genetic Testing (PGT) Market encompasses advanced genetic screening techniques used in assisted reproductive technology (ART) to detect genetic defects in embryos before implantation. PGT aims to improve the success rate of in-vitro fertilization (IVF) by selecting healthy embryos free from genetic abnormalities. This market is driven by the increasing need for precise, non-invasive screening methods, particularly among older prospective parents and couples seeking to reduce the risk of genetic disorders. Key applications of PGT include neurological, gastrointestinal, and skeletal conditions, and the devices are widely used in hospitals, clinics, and homecare settings.

Market Growth Drivers:

The global PGT market is propelled by the rising incidence of infertility and the growing trend of delayed childbearing. Technological advancements, such as next-generation sequencing (NGS) and CRISPR, have revolutionized genetic screening, providing more accurate and efficient results. The increasing awareness of genetic disorders, the integration of personalized medicine, and growing demand for healthier pregnancies are accelerating market growth. Additionally, continuous development of non-invasive testing methods and increasing acceptance of ART are expanding the market's reach.

Market Restraints:

Despite significant growth potential, the PGT market faces challenges related to the high cost of procedures and limited accessibility. Advanced technologies and specialized skills make PGT expensive, restricting its adoption in low-income regions. Moreover, ethical and legal concerns surrounding genetic selection and embryo screening, coupled with varying regulatory environments, hinder widespread acceptance. These factors create barriers to market expansion, particularly in developing regions where insurance coverage for PGT is limited.

Market Opportunities:

The PGT market presents substantial opportunities for manufacturers and healthcare providers due to the integration of personalized medicine and precision health. The increasing demand for tailored healthcare solutions, including PGT, aligns with the global trend of personalized treatment approaches. Companies investing in AI and machine learning to enhance genetic screening accuracy are well-positioned to benefit from this growth. Additionally, expanding direct-to-consumer sales channels and e-commerce platforms offers new avenues for market penetration.

Key Questions Answered in the Report:

• What are the primary factors driving the global PGT market's growth?
• Which types of PGT devices and methods are most widely adopted?
• How are advancements in genetic technology shaping the market?
• Who are the key players in the PGT market, and what strategies are they using to stay competitive?
• What are the future trends and prospects for the global PGT market?

Competitive Intelligence and Business Strategy:

Leading players in the global PGT market focus on innovation, collaboration, and strategic partnerships to strengthen their market position. Companies invest heavily in research and development to improve genetic screening technologies and make PGT more accessible. Collaborations with fertility clinics, hospitals, and healthcare providers enhance product adoption and market penetration. Consumer education and awareness campaigns also play a critical role in expanding the market by reducing the stigma associated with genetic testing.

Key Market Players

• Quest Diagnostics Incorporated
• Natera, Inc.
• COOPER SURGICAL, INC.
• Genea Pty Limited.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Bioarray S.L.
• Illumina, Inc.
• Igenomix
• RGI
• F. Hoffmann-La Roche Ltd.

Market Segmentation

By Procedure

• Genetic Diagnosis
• Genetic Screening

By Product

• Reagents
• Instruments

By Technology

• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)

By Region

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Preimplantation Genetic Testing Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Epidemiology - Disease Prevalence and Incidence
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter’s Five Force Analysis
4. Global Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
4.3. Global Preimplantation Genetic Testing Market Outlook: Test Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
4.3.3.1. Diagnostics
4.3.3.2. Screening
4.4. Market Attractiveness Analysis: Test Type
4.5. Global Preimplantation Genetic Testing Market Outlook: Technology
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
4.5.3.1. CGH-based
4.5.3.2. FISH-based
4.5.3.3. NGS-based
4.5.3.4. SNP-based
4.5.3.5. PCR-based
4.6. Market Attractiveness Analysis: Technology
4.7. Global Preimplantation Genetic Testing Market Outlook: End User
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
4.7.3.1. Infectious Diseases
4.7.3.2. Neurological Diseases
4.7.3.3. Autoimmune Diseases
4.7.3.4. Oncology
4.7.3.5. Others
4.8. Market Attractiveness Analysis: End User
5. Global Preimplantation Genetic Testing Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.2.1. By Country
6.2.2. By Test Type
6.2.3. By Technology
6.2.4. By End User
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
6.4.1. Diagnostics
6.4.2. Screening
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
6.5.1. CGH-based
6.5.2. FISH-based
6.5.3. NGS-based
6.5.4. SNP-based
6.5.5. PCR-based
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
6.6.1. Hospitals
6.6.2. Diagnostic Labs
6.6.3. Research & Academic Institutions
6.6.4. Specialized Clinics
6.6.5. Others
6.7. Market Attractiveness Analysis
7. Europe Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.2.1. By Country
7.2.2. By Test Type
7.2.3. By Technology
7.2.4. By End User
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
7.4.1. Diagnostics
7.4.2. Screening
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
7.5.1. CGH-based
7.5.2. FISH-based
7.5.3. NGS-based
7.5.4. SNP-based
7.5.5. PCR-based
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
7.6.1. Hospitals
7.6.2. Diagnostic Labs
7.6.3. Research & Academic Institutions
7.6.4. Specialized Clinics
7.6.5. Others
7.7. Market Attractiveness Analysis
8. East Asia Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.2.1. By Country
8.2.2. By Test Type
8.2.3. By Technology
8.2.4. By End User
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
8.4.1. Diagnostics
8.4.2. Screening
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
8.5.1. CGH-based
8.5.2. FISH-based
8.5.3. NGS-based
8.5.4. SNP-based
8.5.5. PCR-based
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
8.6.1. Hospitals
8.6.2. Diagnostic Labs
8.6.3. Research & Academic Institutions
8.6.4. Specialized Clinics
8.6.5. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.2.1. By Country
9.2.2. By Test Type
9.2.3. By Technology
9.2.4. By End User
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
9.4.1. Diagnostics
9.4.2. Screening
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
9.5.1. CGH-based
9.5.2. FISH-based
9.5.3. NGS-based
9.5.4. SNP-based
9.5.5. PCR-based
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
9.6.1. Hospitals
9.6.2. Diagnostic Labs
9.6.3. Research & Academic Institutions
9.6.4. Specialized Clinics
9.6.5. Others
9.7. Market Attractiveness Analysis
10. Latin America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.2.1. By Country
10.2.2. By Test Type
10.2.3. By Technology
10.2.4. By End User
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
10.4.1. Diagnostics
10.4.2. Screening
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
10.5.1. CGH-based
10.5.2. FISH-based
10.5.3. NGS-based
10.5.4. SNP-based
10.5.5. PCR-based
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
10.6.1. Hospitals
10.6.2. Diagnostic Labs
10.6.3. Research & Academic Institutions
10.6.4. Specialized Clinics
10.6.5. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.2.1. By Country
11.2.2. By Test Type
11.2.3. By Technology
11.2.4. By End User
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
11.4.1. Diagnostics
11.4.2. Screening
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
11.5.1. CGH-based
11.5.2. FISH-based
11.5.3. NGS-based
11.5.4. SNP-based
11.5.5. PCR-based
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
11.6.1. Hospitals
11.6.2. Diagnostic Labs
11.6.3. Research & Academic Institutions
11.6.4. Specialized Clinics
11.6.5. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping by Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Agilent Technologies Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Abbott Laboratories
12.3.3. CooperSurgical Inc.
12.3.4. Oxford Gene Technology IP
12.3.5. Illumina Inc.
12.3.6. Thermo Fisher Scientific Inc.
12.3.7. PerkinElmer Inc.
12.3.8. Genea Limited
12.3.9. Natera Inc.
12.3.10. Rubicon Genomics Inc.
12.3.11. CombiMatrix Corporation
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations